Vitamin D pathway gene variants and prostate cancer prognosis

Prostate

Volumn 70, Issue 13, 2010, Pages 1448-1460

  Holt, Sarah K ^a   Kwon, Erika M ^b,c   Koopmeiners, Joseph S ^a   Lin, Daniel W ^d   Feng, Ziding ^a,e   Ostrander, Elaine A ^b   Peters, Ulrike ^a,e   Stanford, Janet L ^a,e  

^a Fred Hutchinson Cancer Research Center   (United States)

^b NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

Author keywords

1 alpha hydroxylase; 24 hydroxylase; Outcomes; Prostatic neoplasms; Vitamin D receptor

Indexed keywords

CYTOCHROME P450; OXYGENASE; VITAMIN D; VITAMIN D RECEPTOR; CALCIDIOL 1 MONOOXYGENASE; CALCITRIOL RECEPTOR; STEROID MONOOXYGENASE; VITAMIN D 24 HYDROXYLASE; VITAMIN D 24-HYDROXYLASE;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER GROWTH; CANCER MORTALITY; CANCER RECURRENCE; CANCER RISK; CAUCASIAN; CAUSE OF DEATH; FOLLOW UP; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROSTATE CANCER; SINGLE NUCLEOTIDE POLYMORPHISM; VITAMIN D DEFICIENCY; ALLELE; CASE CONTROL STUDY; DISEASE COURSE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETICS; MORTALITY; PROSTATE TUMOR; RECEIVER OPERATING CHARACTERISTIC;

25-HYDROXYVITAMIN D3 1-ALPHA-HYDROXYLASE; ALLELES; CASE-CONTROL STUDIES; DISEASE PROGRESSION; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSTATIC NEOPLASMS; RECEPTORS, CALCITRIOL; ROC CURVE; STEROID HYDROXYLASES;

EID: 77956645581     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21180     Document Type: Article

References (50)

1. Holick MF,. Vitamin D: Its role in cancer prevention and treatment. Prog Biophys Mol Biol 2006; 92 (1): 49 -59.
2. Krishnan AV, Peehl DM, Feldman D,. Inhibition of prostate cancer growth by vitamin D: Regulation of target gene expression. J Cell Biochem 2003; 88 (2): 363 -371.
3. Bao BY, Yao J, Lee YF,. 1Alpha 25-dihydroxyvitamin D3 suppresses interleukin-8-mediated prostate cancer cell angiogenesis. Carcinogenesis 2006; 27 (9): 1883 -1893.
4. Lim HS, Roychoudhuri R, Peto J, Schwartz G, Baade P, Moller H,. Cancer survival is dependent on season of diagnosis and sunlight exposure. Int J Cancer 2006; 119 (7): 1530 -1536.
5. Robsahm TE, Tretli S, Dahlback A, Moan J,. Vitamin D3 from sunlight may improve the prognosis of breast, colon, and prostate cancer (Norway). Cancer Causes Control 2004; 15 (2): 149 -158.
6. John EM, Schwartz GG, Koo J, Van Den Berg D, Ingles SA,. Sun exposure vitamin D receptor gene polymorphisms and risk of advanced prostate cancer. Cancer Res 2005; 65: 5470 -5479.
7. Schwartz GG, Hanchette CL,. UV latitude and spatial trends in prostate cancer mortality: All sunlight is not the same (United States). Cancer Causes Control 2006; 17 (8): 1091 -1101.
8. Lagunova Z, Porojnicu AC, Dahlback A, Berg JP, Beer TM, Moan J,. Prostate cancer survival is dependent on season of diagnosis. Prostate 2007; 67 (12): 1362 -1370.
9. Johnson MA, Davey A, Park S, Hausman DB, Poon LW,. Age race and season predict vitamin D status in African American and white octogenarians and centenarians. J Nutr Health Aging 2008; 12 (10): 690 -695.
10. American Cancer Society. Cancer facts & figures 2008. Atlanta: American Cancer Society; 2008, pp 1 -68.
11. Vijayakumar S, Mehta RR, Boerner PS, Packianathan S, Mehta RG,. Clinical trials involving vitamin D analogs in prostate cancer. Cancer J 2005; 11 (5): 362 -373.
12. Beer TM, Ryan CW, Venner PM, Petrylak DP, Chatta GS, Ruether JD, Redfern CH, Fehrenbacher L, Saleh MN, Waterhouse DM, Carducci MA, Vicario D, Dreicer R, Higano CS, Ahmann FR, Chi KN, Henner WD, Arroyo A, Clow FW,. Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: A report from the ASCENT investigators. J Clin Oncol 2007; 25 (6): 669 -674.
13. Chen TC, Wang L, Whitlatch LW, Flanagan JN, Holick MF,. Prostatic 25-hydroxyvitamin D-1alpha-hydroxylase and its implication in prostate cancer. J Cell Biochem 2003; 88 (2): 315 -322.
14. Hsu JY, Feldman D, McNeal JE, Peehl DM,. Reduced 1alpha-hydroxylase activity in human prostate cancer cells correlates with decreased susceptibility to 25-hydroxyvitamin D3-induced growth inhibition. Cancer Res 2001; 61 (7): 2852 -2856.
15. Lou YR, Qiao S, Talonpoika R, Syvala H, Tuohimaa P,. The role of vitamin D3 metabolism in prostate cancer. J Steroid Biochem Mol Biol 2004; 92 (4): 317 -325.
16. Luscombe CJ, French ME, Liu S, Saxby MF, Jones PW, Fryer AA, Strange RC,. Outcome in prostate cancer; associations with skin type and polymorphism in pigmentation-related genes. Carcinogenesis 2001; 22 (9): 1343 -1347.
17. Cheteri MB, Stanford JL, Friedrichsen DM, Peters MA, Iwasaki L, Langlois MC, Feng Z, Ostrander EA,. Vitamin D receptor gene polymorphisms and prostate cancer risk. Prostate 2004; 59 (4): 409 -418.
18. Cicek MS, Liu X, Schumacher FR, Casey G, Witt JS,. Vitamin D receptor genotypes/haplotypes and prostate cancer risk. Cancer Epidemiol Biomarkers Prev 2006; 15 (12): 2549 -2552.
19. Mikhak B, Hunter DJ, Spiegelman D, Platz EA, Hollis BW, Giovannucci E,. Vitamin D receptor (VDR) gene polymorphisms and haplotypes interactions with plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D and prostate cancer risk. Prostate 2007; 67 (9): 911 -923.
20. Hawkins GA, Cramer SD, Zheng SL, Isaacs SD, Wiley KE, Chang BL, Bleecker ER, Walsh PC, Meyers DA, Isaacs WB, Xu J,. Sequence variants in the human 25-hydroxyvitamin D3 1-alpha-hydroxylase (CYP27B1) gene are not associated with prostate cancer risk. Prostate 2002; 53 (3): 175 -178.
21. Huang SP, Huang CY, Wu WJ, Pu YS, Chen J,. Association of vitamin D receptor FokI polymorphism with prostate cancer risk clinicopathological features and recurrence of prostate specific antigen after radical prostatectomy. Int J Cancer 2006; 199 (8): 1902 -1907.
22. Xu Y, Shibata A, McNeal JE, Stamey TA, Feldman D, Peehl DM,. Vitamin D receptor start codon polymorphism (FokI) and prostate cancer progression. Cancer Epidemiol Biomarkers Prev 2003; 12 (1): 23 -27.
23. Williams H, Powell IJ, Land SJ, Sakr WA, Hughes MR, Patel NP, Heilbrun LK, Everson RB,. Vitamin D receptor gene polymorphisms and disease free survival after radical prostatectomy. Prostate 2004; 61 (3): 267 -275.
24. Stanford JL, Wicklund KG, McKnight B, Daling JR, Brawer MK,. Vasectomy and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 1999; 8 (10): 881 -886.
25. Agalliu I, Salinas CA, Hansten PD, Ostrander EA, Stanford JL,. Statin use and risk of prostate cancer: Results from a population-based epidemiologic study. Am J Epidemiol 2008; 168 (3): 250 -260.
26. Holt SK, Kwon EM, Lin DW, Ostrander EA, Stanford JL,. Association of Hepsin gene variants with prostate cancer risk and prognosis. Prostate 2010; Epub Feb 17.
27. Penson DF, Albertsen PC, Nelson PS, Barry M, Stanford JL,. Determining cause of death in prostate cancer: Are death certificates valid? J Natl Cancer Inst 2001; 93 (23): 1822 -1823.
28. Nejentsev S, Godfrey L, Snook H, Rance H, Nutland S, Walker NM, Lam AC, Guja C, Ionescu-Tirgoviste C, Undlien DE, Ronningen KS, Tuomilehto-Wolf E, Tuomilehto J, Newport MJ, Clayton DG, Todd JA,. Comparative high-resolution analysis of linkage disequilibrium and tag single nucleotide polymorphisms between populations in the vitamin D receptor gene. Hum Mol Genet 2004; 13 (15): 1633 -1639.
29. Platz EA, Leitzmann MF, Hollis BW, Willett WC, Giovannucci E,. Plasma 1,25-dihydroxy-and 25-hydroxyvitamin D and subsequent risk of prostate cancer. Cancer Causes Control 2004; 15 (3): 255 -265.
30. Tuohimaa P, Tenkanen L, Ahonen M, Lumme S, Jellum E, Hallmans G, Stattin P, Harvei S, Hakulinen T, Luostarinen T, Dillner J, Lehtinen M, Hakama M,. Both high and low levels of blood vitamin D are associated with a higher prostate cancer risk: A longitudinal nested case-control study in the Nordic countries. Int J Cancer 2004; 108 (1): 104 -108.
31. Clayton D, Leung HT,. An R package for analysis of whole-genome association studies. Hum Hered 2007; 64: 45 -51.
32. Holick CN, Stanford JL, Kwon EM, Ostrander EA, Nejentsev S,. Comprehensive association analysis of the vitamin D pathway genes VDR CYP27B1 and CYP24A1 in prostate cancer. Cancer Epidemiol Biomarkers Prev 2007; 16: 1990 -1999.
33. Holt SK, Kwon EM, Peters U, Ostrander EA, Stanford JL,. Vitamin D pathway gene variants and prostate cancer risk. Cancer Epidemiol Biomarkers Prev 2009; 18 (6): 1929 -1933.
34. Jehan F, d'Alesio A, Garabedian M,. Exons and functional regions of the human vitamin D receptor gene around and within the main 1a promoter are well conserved among mammals. J Steroid Biochem Mol Biol 2007; 103 (3-5): 361 -367.
35. Ukaji M, Saito Y, Fukushima-Uesaka H, Maekawa K, Katori N, Kaniwa N, Yoshida T, Nokihara H, Sekine I, Kunitoh H, Ohe Y, Yamamoto N, Tamura T, Saijo N, Sawada J,. Genetic variations of VDR/NR1I1 encoding vitamin D receptor in a Japanese population. Drug Metab Pharmacokinet 2007; 22 (6): 462 -467.
36. Fang Y, van Meurs JB, d'Alesio A, Jhamai M, Zhao H, Rivadeneira F, Hofman A, van Leeuwen JP, Jehan F, Pols HA, Uitterlinden AG,. Promoter and 3'-untranslated-region haplotypes in the vitamin D receptor gene predispose to osteoporotic fracture: The Rotterdam study. Am J Hum Genet 2005; 77 (5): 807 -823.
37. Kidd LC, Paltoo DN, Wang S, Chen W, Akereyeni F, Isaacs W, Ahaghotu C, Kittles R,. Sequence variation within the 5' regulatory regions of the vitamin D binding protein and receptor genes and prostate cancer risk. Prostate 2005; 64 (3): 272 -282.
38. Khorchide M, Lechner D, Cross HS,. Epigenetic regulation of vitamin D hydroxylase expression and activity in normal and malignant human prostate cells. J Steroid Biochem Mol Biol 2005; 93 (2-5): 167 -172.
39. Roff A, Wilson RT,. A novel SNP in a vitamin D response element of the CYP24A1 promoter reduces protein binding transactivation and gene expression. J Steroid Biochem Mol Biol 2008; 112 (1-3): 47 -54.
40. Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC, Partin AW,. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. J Am Med Assoc 2005; 294 (4): 433 -439.
41. Freedland SJ, Giovannucci E, Platz EA,. Are findings from studies of obesity and prostate cancer really in conflict? Cancer Causes Control 2006; 17: 5 -9.
42. Gong Z, Agalliu I, Lin DW, Stanford JL, Kristal AR,. Obesity is associated with increased risks of prostate cancer metastasis and death after initial cancer diagnosis in middle-aged men. Cancer 2007; 109 (6): 1192 -1202.
43. Wortsman J, Matsuoka LY, Chen TC, Lu Z, Holick MF,. Decreased bioavailability of vitamin D in obesity. Am J Clin Nutr 2000; 72 (3): 690 -693.
44. Ochs-Balcom HM, Cicek MS, Thompson CL, Tucker TC, Elston RC, Plummer SJ, Casey G, Li L,. Association of vitamin D receptor gene variants adiposity and colon cancer. Carcinogenesis 2008; 29 (9): 1788 -1793.
45. Li H, Stampfer MJ, Hollis JB, Mucci LA, Gaziano JM, Hunter D, Giovannucci EL, Ma J,. A prospective study of plasma vitamin D metabolites, vitamin D receptor polymorphisms and prostate cancer. PLoS Med 2007; 4 (3): e103.
46. Ahn J, Albanes D, Berndt SI, Peters I, Chatterjee U, Freedman N, Abnet ND, Huang CC, Kibel WY, Crawford AS, Weinstein ED, Chanock SJ, Schatzkin A, Hayes RB,. Vitamin D-related genes, serum vitamin D concentrations and prostate cancer risk. Carcinogenesis 2009; 30 (5): 769 -776.
47. Young MV, Schwartz GG, Wang L, Jamieson DP, Whitlatch LW, Flanagan JN, Lokeshwar BL, Holick MF, Chen TC,. Prostate 25-hydroxyvitamin D-1 alpha-hydroxylase is not influenced by parathyroid hormone and calcium: Implications for prostate cancer chemoprevention by vitamin D. Carcinogenesis 2004; 25 (6): 967 -971.
48. Rukin NJ, Luscombe C, Moon S, Bodiwala D, Liu S, Saxby MF, Fryer AA, Alldersea J, Hoban PR, Strange RC,. Prostate cancer susceptibility is mediated by interactions between exposure to ultraviolet radiation and polymorphisms in the 5' haplotype block of the vitamin D receptor gene. Cancer Lett 2007; 247 (2): 328 -335.
49. Tretli S, Hernes E, Berg JP, Hestvik UE, Robsahm TE,. Association between serum 25(OH)D and death from prostate cancer. Br J Cancer 2009; 100 (3): 450 -454.
50. Egan KM, Signorello LB, Munro HM, Hargreaves MK, Hollis BW, et al. Vitamin D insufficiency among African-Americans in the southeastern United States: Implications for cancer disparities (united states). Cancer Causes Control 2008; 19 (5): 527 -535.